Hochschule für Life Sciences FHNW

Dauerhafte URI für den Bereich

https://irf.fhnw.ch/handle/11654/22

Listen

Auflistung Hochschule für Life Sciences FHNW nach Schlagwort "3D-printing"

Gerade angezeigt 1 - 2 von 2
  • Vorschaubild
    Publikation
    3D printed microfluidic modules. Passive mixers and cells encapsulation in alginate
    (De Gruyter, 02.09.2022) Dalcanale, Federico; Caj, Michaela; Schuler, Felix; Ganeshanathan, Kireedan; Suter-Dick, Laura [in: Current Directions in Biomedical Engineering]
    Passive mixers and droplet generation microfluidic chip modules were designed and manufactured using a commercial SLA 3D-printer. The mixing modules were designed specifically for 3D-printing and evaluated using FEM modeling. The co-flow droplet generator was used for cancer cells encapsulation and drug potency evaluation.
    01A - Beitrag in wissenschaftlicher Zeitschrift
  • Vorschaubild
    Publikation
    Development of immediate release 3D-printed dosage forms for a poorly water-soluble drug by fused deposition modeling. Study of morphology, solid state and dissolution
    (Elsevier, 15.04.2021) Imanidis, Georgios; Fanous, Marina; Bitar, Malak; Gold, Sarah; Sobczuk, Adam; Hirsch, Adam; Ogorka, Joerg [in: International Journal of Pharmaceutics]
    3D-printing technologies such as Fused Deposition Modeling (FDM) bring a unique opportunity for personalized and flexible near-patient production of pharmaceuticals, potentially improving safety and efficacy for some medications. However, FDM-printed tablets often exhibit tendency for slow dissolution due to polymer erosion-based dissolution mechanisms. Development of immediate release (IR) 3D-printed dosage with poorly water-soluble compounds is even more challenging but necessary to ensure wide applicability of the technology within pharmaceutical development portfolios. In this work, process and morphology were considered to achieve IR of BCS class IV compound lumefantrine as model active pharmaceutical ingredient (API) using basic butylated methacrylate copolymer (Eudragit EPO) as matrix former, as well as hydrophilic plasticizer xylitol and pore former maltodextrin. Grid-designed tablets with size acceptable for children from 6 years old and varying programmed infill density were successfully 3D-printed with 5% lumefantrine while higher drug load led to increased brittleness which is incompatible with 3D-printing. Lumefantrine assay was 92 to 97.5% of theoretical content depending on drug load and process parameters. 3D-printed tablets with 65% infill density met rapid release criteria, while 80% and 100% showed slower dissolution. Structural characteristics of 3D-printed tablets with non-continuous surface such as accessible porosity and specific surface area by weight and by volume were quantified by a non-destructive automated µCT-based methodology and were found to correlate with dissolution rate. Increase in accessible porosity, total surface area, specific surface area and decrease in relative density were statistically significant critical factors for modification of lumefantrine dissolution rate. Crystallinity in manufactured tablets and filaments was explored by highly sensitive Raman mapping technique. Lumefantrine was present in the fully amorphous state in the tablets exhibiting adequate stability for on-site manufacturing. The study demonstrates feasibility of immediate release FDM-3D-printed tablets with BCS class IV API and illustrates the correlation of FDM design parameters with morphological and dissolution characteristics of manufactured tablets.
    01A - Beitrag in wissenschaftlicher Zeitschrift